Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel

Amanda N. Fader, Peter G. Rose

Research output: Contribution to journalArticle

Abstract

Background: Paclitaxel is used in the treatment of most gynecologic malignancies. It is solubilized in Cremophor EL, a polyoxyethylated castor oil agent responsible for the high rate of paclitaxel-associated hypersensitivity reactions. Abraxane, a newer, CremophorYfree form of albumin bound paclitaxel has demonstrated an activity and an improved toxicity profile in breast and lung cancers. Case Reports: Five patients with gynecologic cancers (2 ovarian, 2 endometrial, and 1 cervical malignancy) received Abraxane after having a hypersensitivity reaction to paclitaxel. All five patients tolerated Abraxane well, experiencing no reactions or major side effects to the drug. Discussion: Abraxane is well tolerated in women with gynecologic cancer who have experienced a paclitaxel-associated hypersensitivity reaction. Further studies are ongoing to determine the clinical activity of Abraxane in the treatment of these malignancies.

Original languageEnglish (US)
Pages (from-to)1281-1283
Number of pages3
JournalInternational Journal of Gynecological Cancer
Volume19
Issue number7
DOIs
StatePublished - Oct 1 2009
Externally publishedYes

Keywords

  • Abraxane
  • Chemotherapy
  • Hypersensitivity reaction
  • Paclitaxel

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel'. Together they form a unique fingerprint.

  • Cite this